4-1BB immunotherapy: advances and hurdles
Abstract Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated immune functions. Numerous studies have demonstrated the involvement of 4-1BB in infection and tumor immunity. However, t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-01-01
|
| Series: | Experimental and Molecular Medicine |
| Online Access: | https://doi.org/10.1038/s12276-023-01136-4 |
| _version_ | 1797275777730871296 |
|---|---|
| author | Rohit Singh Young-Ho Kim Sang-Jin Lee Hyeon-Seok Eom Beom K. Choi |
| author_facet | Rohit Singh Young-Ho Kim Sang-Jin Lee Hyeon-Seok Eom Beom K. Choi |
| author_sort | Rohit Singh |
| collection | DOAJ |
| description | Abstract Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated immune functions. Numerous studies have demonstrated the involvement of 4-1BB in infection and tumor immunity. However, the clinical development of 4-1BB agonist antibodies has been impeded by the occurrence of strong adverse events, notably hepatotoxicity, even though these antibodies have exhibited tremendous promise in in vivo tumor models. Efforts are currently underway to develop a new generation of agonist antibodies and recombinant proteins with modified effector functions that can harness the potent T-cell modulation properties of 4-1BB while mitigating adverse effects. In this review, we briefly examine the role of 4-1BB in T-cell biology, explore its clinical applications, and discuss future prospects in the field of 4-1BB agonist immunotherapy. |
| first_indexed | 2024-03-07T15:18:22Z |
| format | Article |
| id | doaj.art-bc3cc658acee49bda0bd4bd586d1257f |
| institution | Directory Open Access Journal |
| issn | 2092-6413 |
| language | English |
| last_indexed | 2024-03-07T15:18:22Z |
| publishDate | 2024-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Experimental and Molecular Medicine |
| spelling | doaj.art-bc3cc658acee49bda0bd4bd586d1257f2024-03-05T17:47:55ZengNature Publishing GroupExperimental and Molecular Medicine2092-64132024-01-01561323910.1038/s12276-023-01136-44-1BB immunotherapy: advances and hurdlesRohit Singh0Young-Ho Kim1Sang-Jin Lee2Hyeon-Seok Eom3Beom K. Choi4Immuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer CenterDiagnostics and Therapeutics Technology Branch, Division of Technology Convergence, Research Institute, National Cancer CenterImmuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer CenterHematological Malignancy Center, National Cancer CenterImmuno-oncology Branch, Division of Rare and Refractory Cancer, National Cancer CenterAbstract Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated immune functions. Numerous studies have demonstrated the involvement of 4-1BB in infection and tumor immunity. However, the clinical development of 4-1BB agonist antibodies has been impeded by the occurrence of strong adverse events, notably hepatotoxicity, even though these antibodies have exhibited tremendous promise in in vivo tumor models. Efforts are currently underway to develop a new generation of agonist antibodies and recombinant proteins with modified effector functions that can harness the potent T-cell modulation properties of 4-1BB while mitigating adverse effects. In this review, we briefly examine the role of 4-1BB in T-cell biology, explore its clinical applications, and discuss future prospects in the field of 4-1BB agonist immunotherapy.https://doi.org/10.1038/s12276-023-01136-4 |
| spellingShingle | Rohit Singh Young-Ho Kim Sang-Jin Lee Hyeon-Seok Eom Beom K. Choi 4-1BB immunotherapy: advances and hurdles Experimental and Molecular Medicine |
| title | 4-1BB immunotherapy: advances and hurdles |
| title_full | 4-1BB immunotherapy: advances and hurdles |
| title_fullStr | 4-1BB immunotherapy: advances and hurdles |
| title_full_unstemmed | 4-1BB immunotherapy: advances and hurdles |
| title_short | 4-1BB immunotherapy: advances and hurdles |
| title_sort | 4 1bb immunotherapy advances and hurdles |
| url | https://doi.org/10.1038/s12276-023-01136-4 |
| work_keys_str_mv | AT rohitsingh 41bbimmunotherapyadvancesandhurdles AT younghokim 41bbimmunotherapyadvancesandhurdles AT sangjinlee 41bbimmunotherapyadvancesandhurdles AT hyeonseokeom 41bbimmunotherapyadvancesandhurdles AT beomkchoi 41bbimmunotherapyadvancesandhurdles |